Clinical Trial Update: A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of grazoprevir with pegylated interferon alfa-2b and ribavirin in treatment-naïve chronic hepatitis C patients; complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir (MK-5172) (Grazoprevir)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C (CHC) | Phase 2 | Status: COMPLETED | Results posted: 2016-03-04